Notes / Company

Krebs Biochemicals & Industries Ltd.

KREBSBIO BSE 524518 ISIN INE268B01013 Pharmaceuticals

Fundamentals

Market cap: ₹143 cr
ROE: 18.48%
Debt / equity: -1.45
52-week range: 38.33 — 91.90

Research on Tijori Finance

Company snapshot

Krebs Biochemicals & Industries Ltd.

Pharmaceuticals

₹122 cr

Latest quarter · Mar 2026

Sales₹7 cr

Net profit−₹2 cr

Op. margin−12.8%

EPS−₹1.09

Strength & growth

Debt / equity-1.45×

Current ratio0.10×

Sales CAGR+33.1%

The timeline — 1 note on Krebs Biochemicals & Industries Ltd.

May 2026

21 May 26 · 1:24 PM IST Brief

Brief · Earnings · Micro cap

Krebs Biochemicals revenue halved as Vizag plant stays shut

FY26 revenue fell to ₹2,373.16 lacs from ₹4,331.19 lacs; net loss narrowed to ₹1,693.31 lacs but net worth deepened to negative ₹16,275.47 lacs. Plant remains closed since Feb 2025.

Verify on exchange BSE filings for KREBSBIO NSE filings for KREBSBIO Tijori Finance company page